Oculis Holding AG Ordinary shares

Yahoo Finance • 16 hours ago

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to be presented by Baruch Kuppermann, M.D., Ph.D.New post-hoc analysis of... Full story

Yahoo Finance • 2 months ago

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology... Full story

Yahoo Finance • 2 months ago

Oculis Appoints Katie Kazem as Chief Legal Officer

Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companiesChief Legal Officer (CLO) appointment enhances... Full story

Yahoo Finance • 5 months ago

Pre-Market Earnings Report for November 18, 2025 : HD, PDD, MDT, BIDU, ESLT, AS, BZ, JHX, BRBR, ENR, WB, OCSL

The following companies are expected to report earnings prior to market open on 11/18/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Home Depot, Inc. (HD)is reporting for the quarter ending October 31... Full story

Yahoo Finance • 6 months ago

Oculis Holding GAAP EPS of CHF -0.32

* Oculis Holding press release [https://seekingalpha.com/pr/20301359-oculis-reports-q3-2025-financial-results-and-provides-company-update] (OCS [https://seekingalpha.com/symbol/OCS]): Q3 GAAP EPS of CHF -0.32. * Operating income of CHF... Full story

Yahoo Finance • 6 months ago

Oculis Reports Q3 2025 Financial Results and Provides Company Update

ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) andNon-arteritic Anterior Ischemic Optic Neuropathy... Full story

Yahoo Finance • 6 months ago

Oculis birtir uppgjör fyrir þriðja ársfjórðung 2025 og kynnir áfanga í rekstri félagsins

ZUG, Sviss, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Oculis hraðar þróunaráætlun sinni í kjölfar árangursríks fundar með Matvæla- og lyfjastofnun Bandaríkjanna (FDA), með PIONEER-rannsóknaráætluninni á Privosegtor sem meðferð við bráðri sjónta... Full story

Yahoo Finance • 6 months ago

Oculis to Participate in Upcoming November Investor Conferences

ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophtha... Full story

Yahoo Finance • 6 months ago

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs... Full story

Yahoo Finance • 6 months ago

Oculis greinir frá umframeftirspurn í 110 milljóna USD fjármögnun sem er ætlað til að hraða klínískri þróun Privosegtor

ZUG, Sviss, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) („Oculis“ eða „félagið“), alþjóðlegt líftæknilyfjafyrirtæki með áherslu á á nýsköpun til að meðhöndla augnsjúkdóma og augntaugasjúkdóma og mæta veru... Full story

Yahoo Finance • 7 months ago

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significan... Full story

Yahoo Finance • 7 months ago

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program, which includes mu... Full story

Yahoo Finance • 7 months ago

Oculis hrindir af stað skráningarrannsóknum á Privosegtor við bráðri sjóntaugabólgu, sem gæti orðið fyrsta taugaverndandi meðferð sinnar tegundar

ZUG, Sviss, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Árangursríkur fundur með Matvæla- og lyfjastofnun Bandaríkjanna (FDA) skapar möguleika á að hefja skráningarrannsóknir á Privosegtor sem meðferð við bráðri sjóntaugabólgu (e. Acute Optic Neur... Full story

Yahoo Finance • 7 months ago

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial... Full story

Yahoo Finance • 8 months ago

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet me... Full story

Yahoo Finance • 8 months ago

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 eye drops in diabetic macular edema (DM... Full story

Yahoo Finance • 8 months ago

Citi initiates Lumentum coverage with Buy, citing AI optics leadership

[Lumentum Corporate Headquarters in San Jose, California, USA] JHVEPhoto Citi initiated coverage on Lumentum Holdings (NASDAQ:LITE [https://seekingalpha.com/symbol/LITE]) with a Buy rating, expecting more upside in the stock, beyond its c... Full story

Yahoo Finance • 8 months ago

Oculis to Participate in Upcoming September Investor Conferences

ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovative solutions for ophthalmic and neuro-ophthalmic diseases with s... Full story

Yahoo Finance • 8 months ago

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors

Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in neuro-ophthalmologySeba... Full story

Yahoo Finance • 8 months ago

Oculis Holding stock price target raised to $33 from $32 at H.C. Wainwright

Investing.com - H.C. Wainwright raised its price target on Oculis Holding AG (NASDAQ:OCS) to $33.00 from $32.00 on Friday, while maintaining a Buy rating on the stock. Currently trading at $17.80, the stock sits within a broader analyst ta... Full story